Global /United States /Healthcare /Drug Manufacturers - General /APRE

Aprea Therapeutics, Inc.

APRE

• NASDAQ: APRE • Delayed

0.8190USD -2.1%

As of 13 June 2026, Aprea Therapeutics, Inc. has a market cap of $9.38M USD, ranking #41628 globally and #5371 in the United States. It ranks #3688 in the Healthcare sector, and #1198 in the Drug Manufacturers - General industry.

Global Rank

41628

Country Rank

5371

Sector Rank

3688

Industry Rank

1198

Key Stats

Market Cap

$9.38MUSD

Enterprise Value

-$5.01MUSD

Revenue (TTM)

$285.76KUSD

EBITDA (TTM)

-$13.21MUSD

Net Income (TTM)

-$12.6MUSD

PS Ratio

33.5

PB Ratio

0.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Oren Gilad open_in_new

Employees

Founded

2006

IPO

03 Oct 2019

Website

aprea.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	-14%	20%	7.2%	-42%	-4%	-53%	-79%	-99%

News

APRE Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	APRE Aprea Therapeutics Inc ISIN: US03836J2015 Shares Out.: Shares Outstanding: 12.383M¹ Shares Float: 10.706M² TV: TradingView: NASDAQ: APRE SA: Stock Analysis: NASDAQ: APRE YF: Yahoo Finance: APRE GF: Google Finance: NASDAQ: APRE NQ: NASDAQ: APRE BA: Barron's: APRE MS: Morningstar: XNAS: APRE	0.8190 USD	TV: TradingView: NASDAQ: APRE SA: Stock Analysis: NASDAQ: APRE YF: Yahoo Finance: APRE GF: Google Finance: NASDAQ: APRE NQ: NASDAQ: APRE BA: Barron's: APRE MS: Morningstar: XNAS: APRE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 8M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 6M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 4M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 3M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 2M%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 1M%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 3M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 3M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 3M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 2M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 1M%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 1M%	14.6	United Kingdom

chevron_leftBack